Skip to main content
Veterinary Medicines

MAMICUR

Authorised
  • Cloxacillin sodium
  • NEOMYCIN SULFATE
  • Dexamethasone
  • Trypsin

Product identification

Medicine name:
МАМИКУР
MAMICUR
Active substance:
  • Cloxacillin sodium
  • NEOMYCIN SULFATE
  • Dexamethasone
  • Trypsin
Target species:
  • Cattle
  • Goat
Route of administration:
  • Intramammary use

Product details

Active substance and strength:
  • Cloxacillin sodium
    250.00
    milligram(s)
    /
    1.00
    Syringe
  • NEOMYCIN SULFATE
    100.00
    milligram(s)
    /
    1.00
    Syringe
  • Dexamethasone
    0.50
    milligram(s)
    /
    1.00
    Syringe
  • Trypsin
    5.00
    milligram(s)
    /
    1.00
    Syringe
Pharmaceutical form:
  • Intramammary suspension
Withdrawal period by route of administration:
  • Intramammary use
    • Cattle
      • Meat and offal
        7
        day
      • Milk
        3
        day
    • Goat
      • Meat and offal
        7
        day
      • Milk
        3
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ51RC26
Authorisation status:
  • Valid
Authorised in:
  • Bulgaria
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Farma Sis OOD
Marketing authorisation date:
Manufacturing sites for batch release:
  • Laboratorios Syva S.A.U.
Responsible authority:
  • Bulgarian Agency For Food Safety
Authorisation number:
  • 0022-1530
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Bulgarian (PDF)
Published on: 10/08/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."